Navigation Links
Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
Date:11/2/2011

pectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Such forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause the results to differ materially from those expressed or implied by such forward-looking statements. Although these forward-looking statements reflect the good faith judgment of Regulus' management, these statements are based only on facts and factors currently known by Regulus. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Regulus', Alnylam's, and Isis' programs are described in additional detail in Alnylam's and Isis' annual reports on Form 10-K for the year ended December 31, 2010, and its most recent quarterly report on Form 10-Q.  Copies of these and other documents are available from Alnylam or Isis.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Webinar Advisory: Regulus to Host Discussion About Potential of microRNA-33 as Target for Treatment of Atherosclerosis
2. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
3. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
4. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
5. Echo Therapeutics Announces Warrant Exercise by Its Largest Shareholder
6. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
7. Pearl Therapeutics Presents New Scientific Evidence Supporting Versatility of Its Novel Cosuspension MDI Platform
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
10. Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018
11. Osteoarthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... , Nov. 23, 2014 Anthera Pharmaceuticals, ... Paul F. Truex , President and Chief Executive ... Annual Piper Jaffray Healthcare Conference. Anthera ... at the Palace Hotel in New York ... Anthera Pharmaceuticals is a biopharmaceutical company focused ...
(Date:11/22/2014)... -- Sprout Pharmaceuticals today announced positive preliminary results from a Phase ... up to 200 mg at bedtime had no next-day impairment ... th Annual Fall Scientific Meeting of the Sexual Medicine ... Miami . The Phase 1 driving ... and the Formal Dispute Resolution that was filed in December ...
(Date:11/22/2014)... Nov. 21, 2014  CytoSorbents Corporation (OTCQB: CTSO), ... Union approved CytoSorb® cytokine adsorber to treat critically-ill ... Beacon of Light Award at last night,s New ... Dr. Phillip Chan , Chief Executive ... to be recognized by the New Jersey Tech ...
Breaking Medicine Technology:Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... 29, 2011 Breast cancer patients and their families ... (FDA) decision to remove the anti-cancer drug Avastin from ... breast cancer. Terry Kalley, founder of the ... the decision, saying, "While this vote is disappointing, it ...
... Mass., June 29, 2011 NxStage® Medical, Inc. (Nasdaq: ... dialysis products, announced that it has entered into a ... move its corporate headquarters to the revitalized historic mill ... Street, Lawrence, MA.  The move, which is expected to ...
Cached Medicine Technology:Breast Cancer Patients and Families Decry FDA Panel Vote to Remove Life Saving Drug From Approved List 2NxStage® Enters Into New Lease for Corporate Headquarters Within Lawrence, MA 2
(Date:11/26/2014)... (HealthDay News) -- Teens prescribed anti-anxiety or sleep ... drugs than other teens, a new study warns. ... substance abuse assessments on teenagers before prescribing these ... and parents don,t realize the abuse potential," said ... University of Michigan School of Nursing. "These drugs ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, ... Nexium may disrupt the makeup of bacteria in the digestive ... a small new study suggests. The research doesn,t ... become ill, and study authors aren,t recommending that anyone stop ... "should be used at the lowest dose that provides adequate ...
(Date:11/24/2014)... November 24, 2014 The Healthy Skin ... reviews of affordable skin care products, recently announced its ... offers readers a wide variety of articles, tips, and ... as organic skincare alternatives. , According to Emily Lataille, ... main content includes thoroughly researched reviews, tips for the ...
(Date:11/24/2014)... 2014 Abington Health is ... has joined The Neurology Group and has been named ... , A graduate of Vinnica Medical University in ... Einstein Medical Center in Philadelphia and completed a fellowship ... Center at Weill Cornell Medical College. Ternopolska is board ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Recently, SweetDressy.com, ... industry, unveiled its new collection of 2014 Evening Dresses. ... now. According to the company’s marketing manager, the special ... http://www.sweetdressy.com/evening-dresses.html for more. , Sweetdressy.com has been working ... pleased to unveil the latest designs. Their new dresses ...
Breaking Medicine News(10 mins):Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3Health News:Skin Care Advice Blog The Healthy Skin Care Journal Now Accessible to the Public 2Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2
... (October 28, 2010) University of Minnesota Medical School ... a correlation between increased circuit activity in the right ... triggered by post traumatic stress disorder (PTSD). The ... neural activity, its impact and its manifestation is the ...
... News) -- Improving mothers, literacy skills may boost the ... study. U.S. researchers concluded that a mother,s reading ... critical factor influencing her children,s future academic success, even ... neighborhood income. For their study, the researchers examined ...
... American Academy of Pediatrics (AAP) recommends that parents limit combined ... 2 hours per day for preschool-age children. In a ... Pediatrics , researchers found that many children are exposed to ... with 66% exceeding the recommended daily amount. According to ...
... opinion polls, including newly released data, shows that those who ... in 2010 and those who say they intend to vote ... of what they want the future of health reform legislation ... in Congress on this issue. Nearly three-fourths (73%) ...
... Oct. 27 (HealthDay News) -- When it comes to feelings, ... People tend to have worse and more intense views on ... that have already taken place. The observation touches upon ... people apparently take more extreme positions regarding events that have ...
... evolution in action in cancer cells. They show the ... only is cancer genetically different between different patients, but ... has acquired distinct mutations. Effectively, ten different ... tumours. The complexity of pancreatic cancer genetics uncovered in ...
Cached Medicine News:Health News:U of M researchers identify possible key to treating, understanding post-traumatic stress disorder 2Health News:Moms' Literacy Pivotal to Kids' Academic Success 2Health News:New study suggests most preschool-age children exceed daily screen time recommendations 2Health News:Prospective voters and the new health care law 2Health News: Future Seems to Be Viewed More Harshly Than Past 2Health News:Forces for cancer spread: Genomic instability and evolutionary selection 2Health News:Forces for cancer spread: Genomic instability and evolutionary selection 3
Ferris Smith Rongeurs, 12 overall length 300 mm....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
It is designed for rigid skeletal fixation. These pins are constructed of stainless steel and can be removed for sterilization and reuse....
... It is designed for ... the surgeon greater freedom in ... 3-point rigid skeletal fixation is ... lateral, or sitting positions. Craniotomies ...
Medicine Products: